山东博苑医药化学股份有限公司 董事、高级管理人员离职管理制度 山东博苑医药化学股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第一条 为规范山东博苑医药化学股份有限公司（以下简称"公司"）董事、 高级管理人员离职管理，保障公司治理稳定性和股东的合法权益，根据《中华 人民共和国公司法》《上市公司章程指引》《深圳证券交易所创业板股票上市 规则》《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司规范 运作》等相关法律、法规、规范性文件以及《山东博苑医药化学股份有限公司 章程》（以下简称"《公司章程》"）的有关规定，结合公司的实际情况，特 制定本制度。 第二条 本制度适用于公司全体董事（包括非独立董事、独立董事及职工代 表董事）和高级管理人员因任期届满、辞任、被解除职务或其他原因离职的情 形。 第二章 离职情形与程序 第三条 公司董事、高级管理人员可以在任期届满前辞任，董事、高级管理 人员辞任应当向公司董事会提交书面辞职报告。 辞职报告中应说明辞职原因、辞去的职务以及辞职后是否继续在公司及控 股子公司任职（如继续任职，说明继续任职的情况），是否存在未履行完毕的 公开承诺（如存在，说明相关保障措施 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-042 山东博苑医药化学股份有限公司 关于修订《公司章程》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 4 一、修订《公司章程》的相关情况 根据《中华人民共和国公司法》（2023年修订）和《上市公司章程指引》 （2025年修订）的相关规定，结合公司的实际情况，公司将相应增加、调整公司 治理相关规定的内容，并对现行《公司章程》进行全面修订。此次修订涉及《公 司章程》全篇，为突出本次修订的重点，本公告仅就重要条款的修订对比作出展 示，其余只涉及部分文字表述的调整内容将不再逐一比对，《公司章程》修订对 照表如下： | 原章程内容 | 修订后的章程内容 | | --- | --- | | 第一条 为维护山东博苑医药化学股份有 | 第一条 为维护山东博苑医药化学股份有 | | 限公司（以下称"公司"或"本公司"）、股 | 限公司（以下称"公司"或者"本公司"）、 | | 东和债权人的合法权益，规范公司的组织和行 | 股东、职工和债权人的合法权益，规范公司的 | | 为，根据《中华人民共和国公司法》 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-043 山东博苑医药化学股份有限公司 关于首发部分募投项目变更、结项并将节余募集资金投入新 项目的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"或"博苑股份"）于 2025 年 8 月 18 日召开了第二届董事会第十次会议及第二届监事会第八次会议， 会议审议通过了《关于首发部分募投项目变更、结项并将节余募集资金投入新项 目的议案》，为提高募集资金使用效率，根据公司现阶段经营发展的需要，同意 公司将首次公开发行股票募集资金投资项目"100 吨/年贵金属催化剂、60 吨/ 年高端发光新材料、4100 吨/年高端有机碘、溴新材料项目"的投资总额进行调 整并结项，将节余募集资金用于新项目"山东博苑医药化学股份有限公司创新研 发中心项目"（以下简称"创新研发中心项目"）。 本次部分募投项目变更、结项并将节余募集资金投入新项目的事项不构成关 联交易，也不构成《上市公司重大资产重组管理办法》规定的重大资产重组，保 荐机构对该事项出具了无异议的核查意见，该事项 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山东博苑医药化学股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日召 开了第二届董事会第十次会议，审议通过了《关于召开 2025 年第三次临时股东 会的议案》，决定于 2025 年 9 月 4 日召开公司 2025 年第三次临时股东会（以下 简称"本次会议"或"本次股东会"），现将本次会议的有关情况通知如下： 证券代码：301617 证券简称: 博苑股份 公告编号：2025-041 山东博苑医药化学股份有限公司 关于召开 2025 年第三次临时股东会的通知 （2）网络投票时间： 3、会议召开的合法、合规性：本次股东会的召集、召开符合有关法律、行 政法规、部门规章、其他规范性文件及《公司章程》的有关规定。 4、会议召开的日期与时间： （1）现场会议召开时间：2025 年 9 月 4 日（星期四）下午 15:00 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：公司第二届董事会 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 9 月 4 日上 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-036 山东博苑医药化学股份有限公司 第二届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东博苑医药化学股份有限公司（以下简称"公司"）第二届监事会第八次会 议通知于 2025 年 8 月 7 日以电子邮件的形式发出，2025 年 8 月 18 日于公司会 议室通过现场会议方式召开。本次会议应出席监事 3 人，实际出席监事 3 人。会 议由监事会主席于福强先生召集并主持。会议的通知及召开程序符合相关法律法 规和《公司章程》的规定，会议合法、有效。全体监事审议并通过了如下议案： 二、监事会会议审议情况 表决结果：3 票赞成，0 票弃权，0 票反对。 2、审议通过《关于公司<2025 年半年度募集资金存放、管理与使用情况专 项报告>的议案》 公司已按照相关法律法规和公司《募集资金管理制度》的规定和要求使用募 集资金，并及时、真实、准确、完整地披露了报告期内募集资金存放与使用情况， 不存在募集资金存放、使用、管理及披露的违规情形。 具体内容详见公司披 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-035 山东博苑医药化学股份有限公司 第二届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东博苑医药化学股份有限公司（以下简称"公司"）第二届董事会第十次会 议通知于 2025 年 8 月 7 日以电子邮件的形式发出，2025 年 8 月 18 日于公司会 议室通过"现场+通讯"的方式召开。本次会议应出席董事 7 人，实际出席董事 7 人（其中袁瑞、高磊、张志红通过通讯方式参加会议）。会议由董事长李成林 先生召集并主持，公司监事及高级管理人员列席了会议。会议的通知及召开程序 符合相关法律法规和《公司章程》的规定，会议合法、有效。全体董事审议并通 过了如下议案： 二、董事会会议审议情况 1、审议通过《关于公司<2025 年半年度报告>全文及其摘要的议案》 公司编制 2025 年半年度报告及其摘要的程序符合法律、行政法规和中国证 监会的规定，报告真实、准确、完整地反映了公司经营、管理及财务等各方面的 实际情况，不存在虚假记载、误导性陈述或重大遗漏。 ...

证券代码：301617 证券简称：博苑股份 公告编号：2025-040 山东博苑医药化学股份有限公司 关于公司 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、审议程序 三、本次利润分配预案的合理性说明 1、本次利润分配预案符合《公司法》《企业会计准则》《上市公司监管指 引第 3 号——上市公司现金分红》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定，符合公司的利润 分配政策、股东分红回报规划以及做出的相关承诺，有利于全体股东共享公司经 营成果。 山东博苑医药化学股份有限公司（以下简称"公司"）于 2025 年 8 月 18 日 召开第二届董事会第十次会议、第二届监事会第八次会议，分别审议通过了《关 于公司 2025 年半年度利润分配预案的议案》。本次利润分配预案满足公司于 2025 年 5 月 15 日召开的 2024 年年度股东会审议通过的《关于提请股东会授权董事会 制定 2025 年中期分红方案的议案》，无需再次提交股东会审议。 二、2025 年半年度利润分配预 ...

Part I Important Notes, Table of Contents, and Definitions [Important Notes](index=2&type=section&id=Important%20Notes) The Board of Directors, Supervisory Board, and senior management guarantee the accuracy and completeness of the semi-annual report, assuming legal responsibility - Company's Board of Directors, Supervisory Board, and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report, bearing individual and joint legal responsibility [5](index=5&type=chunk) - Company's responsible person Yu Guoqing, chief accountant Sun Teng, and head of accounting department Sun Teng declare the financial report is true, accurate, and complete [5](index=5&type=chunk) 2025 Semi-Annual Profit Distribution Plan | Indicator | Content | | :--- | :--- | | Distribution Basis | Total share capital 133,640,000 shares | | Cash Dividend | 2 yuan per 10 shares (including tax) | | Bonus Shares | 0 shares (including tax) | | Capital Reserve to Share Capital | No transfer | [Table of Contents](index=3&type=section&id=Table%20of%20Contents) This report's clear table of contents outlines eight main chapters, covering company profile, financial indicators, MD&A, corporate governance, significant matters, share changes, bond information, and financial reports - The report comprises eight main chapters, structured clearly for easy reference [7](index=7&type=chunk) [List of Documents for Reference](index=4&type=section&id=List%20of%20Documents%20for%20Reference) The list includes signed financial statements, the original semi-annual report, and publicly disclosed company documents, all available at the company's securities affairs department - Documents for reference include signed and sealed financial statements, the original semi-annual report signed by the legal representative, original drafts of publicly disclosed documents, and other relevant materials [9](index=9&type=chunk) - All documents for reference are kept at the company's securities affairs department [10](index=10&type=chunk) [Definitions](index=5&type=section&id=Definitions) This section defines common terms used in the report, including company names, reporting period, subsidiaries, related parties, currency units, and specialized chemical terms - "Boyuan Chemical" refers to Shandong Boyuan Pharmaceutical Chemical Co., Ltd., established on September 29, 2020 [11](index=11&type=chunk) - "Reporting Period" refers to January 1, 2025, to June 30, 2025 [11](index=11&type=chunk) - "Fine Chemicals" are defined as chemical products with specific application functions, high technology intensity, strong marketability, and high added value [11](index=11&type=chunk) Part II Company Profile and Key Financial Indicators [I. Company Profile](index=6&type=section&id=I.%20Company%20Profile) Shandong Boyuan Pharmaceutical Chemical Co., Ltd. (Stock Abbreviation: Boyuan Chemical, Stock Code: 301617) is listed on the Shenzhen Stock Exchange, with Yu Guoqing as its legal representative Company Basic Information | Indicator | Content | | :--- | :--- | | Stock Abbreviation | Boyuan Chemical | | Stock Code | 301617 | | Listed Exchange | Shenzhen Stock Exchange | | Chinese Name | 山东博苑医药化学股份有限公司 | | Legal Representative | Yu Guoqing | [II. Contact Persons and Information](index=6&type=section&id=II.%20Contact%20Persons%20and%20Information) Company Board Secretary Zhang Shangang and Securities Affairs Representative Yang Yanli maintain consistent contact details for address, phone, fax, and email Company Contact Information | Position | Name | Contact Address | Phone | Fax | Email | | :--- | :--- | :--- | :--- | :--- | :--- | | Board Secretary | Zhang Shangang | 200 meters north of the intersection of Xinhai Road and Dajiu Road, Houzhen Marine Chemical Industrial Park, Shouguang City, Shandong Province | 0536-2099456 | 0536-2099456 | boyuangufen@boyuanchemical.com | | Securities Affairs Representative | Yang Yanli | 200 meters north of the intersection of Xinhai Road and Dajiu Road, Houzhen Marine Chemical Industrial Park, Shouguang City, Shandong Province | 0536-2099456 | 0536-2099456 | boyuangufen@boyuanchemical.com | [III. Other Information](index=6&type=section&id=III.%20Other%20Information) The company's contact information, disclosure, and document storage locations remained unchanged, but its registration status was updated on June 16, 2025 - Company's registered address, office address, website, and email contact information remained unchanged during the reporting period [15](index=15&type=chunk) - Information disclosure and document storage locations remained unchanged during the reporting period [16](index=16&type=chunk) - The company's registration status changed during the reporting period, completing industrial and commercial change registration and obtaining a new business license on June 16, 2025 [17](index=17&type=chunk)[18](index=18&type=chunk) [IV. Key Accounting Data and Financial Indicators](index=7&type=section&id=IV.%20Key%20Accounting%20Data%20and%20Financial%20Indicators) The company's operating revenue increased by **7.39%** to **747 million yuan**, but net profit attributable to shareholders decreased by **18.97%** to **99 million yuan**, with a significant **93.24%** drop in net cash flow from operating activities Key Accounting Data and Financial Indicators (Year-on-Year Change) | Indicator | Current Period (Yuan) | Prior Year Adjusted (Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 746,785,655.59 | 695,401,498.69 | 7.39% | | Net Profit Attributable to Shareholders | 99,042,904.65 | 122,234,977.61 | -18.97% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 98,976,633.90 | 122,072,686.16 | -18.92% | | Net Cash Flow from Operating Activities | 8,000,572.25 | 118,422,705.70 | -93.24% | | Basic Earnings Per Share (Yuan/Share) | 0.7411 | 1.5854 | -53.25% | | Diluted Earnings Per Share (Yuan/Share) | 0.7411 | 1.5854 | -53.25% | | Weighted Average Return on Net Assets | 6.08% | 13.94% | -7.86% | Balance Sheet Key Indicators (Period-End Change) | Indicator | Current Period End (Yuan) | Prior Year End Adjusted (Yuan) | Change | | :--- | :--- | :--- | :--- | | Total Assets | 1,838,103,264.00 | 1,883,818,139.55 | -2.43% | | Net Assets Attributable to Shareholders | 1,682,199,347.23 | 1,656,652,466.88 | 1.54% | [V. Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=8&type=section&id=V.%20Differences%20in%20Accounting%20Data%20Under%20Domestic%20and%20Overseas%20Accounting%20Standards) The company reports no differences in net profit and net assets between international or overseas accounting standards and Chinese accounting standards for the reporting period - The company reports no differences in net profit and net assets between financial reports disclosed under international accounting standards and Chinese accounting standards during the reporting period [20](index=20&type=chunk) - The company reports no differences in net profit and net assets between financial reports disclosed under overseas accounting standards and Chinese accounting standards during the reporting period [21](index=21&type=chunk) [VI. Non-Recurring Gains and Losses and Amounts](index=8&type=section&id=VI.%20Non-Recurring%20Gains%20and%20Losses%20and%20Amounts) Non-recurring gains and losses totaled **66,270.75 yuan** for the period, primarily from non-current asset disposal, government grants, entrusted investments, and net profit from business combinations under common control Non-Recurring Gains and Losses and Amounts | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | -2,520,770.57 | | Government Grants Included in Current Profit/Loss | 293,495.05 | | Gains/Losses from Entrusted Investment or Asset Management | 2,816,907.19 | | Net Profit/Loss from Subsidiaries Acquired Under Common Control from Beginning of Period to Combination Date | -70,014.53 | | Other Non-Operating Income and Expenses Apart from the Above | 3,129.38 | | Less: Income Tax Impact | 456,475.77 | | Total | 66,270.75 | - The company has no other profit/loss items meeting the definition of non-recurring gains and losses, nor has it classified non-recurring gains and losses as recurring gains and losses [23](index=23&type=chunk)[24](index=24&type=chunk) Part III Management Discussion and Analysis [I. Main Business Activities During the Reporting Period](index=9&type=section&id=I.%20Main%20Business%20Activities%20During%20the%20Reporting%20Period) As a high-tech enterprise, the company specializes in R&D, production, and sales of fine chemicals and resource utilization, with growing sales in iodides and stable market position in specialty functional chemicals - The company's main businesses include iodides, specialty functional chemicals, and trading, with products used in pharmaceuticals, chemicals, optoelectronic materials, feed, and food [26](index=26&type=chunk) - The fine chemical industry is a key area for upgrading traditional chemical industries, and stricter domestic environmental policies favor compliant enterprises [26](index=26&type=chunk) - Iodine series chemicals are primarily used in pharmaceutical manufacturing (contrast agents) and polarizer production; influenced by growing market demand, the company's iodide sales continued to increase year-on-year [27](index=27&type=chunk) - Specialty functional chemicals include luminescent materials, hexamethyldisilazane, and precious metal catalysts, with hexamethyldisilazane sales showing a year-on-year growth trend [28](index=28&type=chunk) [II. Analysis of Core Competencies](index=9&type=section&id=II.%20Analysis%20of%20Core%20Competencies) The company's core strengths lie in circular development, comprehensive services, strong R&D, high product quality, established customer base, leading industry position, and strict compliance - The company converts waste into raw materials through resource comprehensive utilization technology, reducing costs and providing integrated full-产业链 services to enhance customer loyalty [29](index=29&type=chunk) - The company possesses a stable and professional R&D team, holding **51 patents (27 invention patents)** as of June 30, 2025, along with multiple provincial-level R&D platforms and honors [30](index=30&type=chunk)[31](index=31&type=chunk) - The company has established a comprehensive quality control system, with main products certified by ISO9001 and ISO22000, fostering long-term partnerships with renowned clients [32](index=32&type=chunk) - The company's iodide and luminescent material products maintain a long-term leading market share and have participated in drafting **3 industry standards and 12 group standards**, enhancing industry influence [33](index=33&type=chunk) - Adhering to compliant development, the company holds complete qualifications for hazardous chemical production and hazardous waste utilization, continuously increasing investment in safety and environmental protection, and was recognized as an "Outstanding Unit for Annual Ecological Environmental Protection Work" [34](index=34&type=chunk) [III. Main Business Analysis](index=10&type=section&id=III.%20Main%20Business%20Analysis) Operating revenue grew by **7.39%**, but cost of sales increased more rapidly, impacting profit. Net cash flow from operating activities significantly decreased by **93.24%** due to increased payments for goods and services. Iodide revenue grew by **16.56%**, but its gross margin declined by **7.13%** Year-on-Year Changes in Key Financial Data | Indicator | Current Period (Yuan) | Prior Year (Yuan) | YoY Change | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Operating Revenue | 746,785,655.59 | 695,401,498.69 | 7.39% | | | Operating Cost | 585,502,141.36 | 510,857,620.48 | 14.61% | | | Selling Expenses | 5,214,686.25 | 5,358,960.52 | -2.69% | | | Administrative Expenses | 15,663,173.48 | 13,673,419.97 | 14.55% | | | Financial Expenses | -13,837.06 | -732,684.55 | 98.11% | Primarily due to decreased interest income and increased exchange losses | | Income Tax Expense | 13,475,248.34 | 18,012,499.86 | -25.19% | | | R&D Investment | 25,455,264.25 | 21,508,849.44 | 18.35% | | | Net Cash Flow from Operating Activities | 8,000,572.25 | 118,422,705.70 | -93.24% | Primarily due to increased cash payments for goods and services | | Net Cash Flow from Investing Activities | -366,852,634.94 | -25,199,570.82 | -1,355.79% | Primarily due to purchase of bank wealth management products | | Net Cash Flow from Financing Activities | -78,332,739.72 | -1,079,342.48 | -7,157.45% | Primarily due to dividend distribution to shareholders | | Net Increase in Cash and Cash Equivalents | -438,222,467.68 | 91,517,909.78 | -578.84% | Primarily due to purchase of bank wealth management products | Products or Services Accounting for Over 10% of Revenue | Product or Service | Operating Revenue | Operating Cost | Gross Margin | YoY Change in Operating Revenue | YoY Change in Operating Cost | YoY Change in Gross Margin | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Iodides | 556,780,237.55 | 416,936,706.82 | 25.12% | 16.56% | 28.82% | -7.13% | | Specialty Functional Chemicals | 95,476,711.03 | 84,023,221.52 | 12.00% | -16.10% | -16.15% | 0.06% | [IV. Non-Core Business Analysis](index=11&type=section&id=IV.%20Non-Core%20Business%20Analysis) The company has no non-core business analysis for the reporting period, indicating a focus on its primary fine chemical operations - The company has no non-core business analysis for the reporting period [39](index=39&type=chunk) [V. Analysis of Assets and Liabilities](index=11&type=section&id=V.%20Analysis%20of%20Assets%20and%20Liabilities) Total assets decreased by **2.43%** year-on-year, with a significant **23.22%** reduction in monetary funds due to bank wealth management product purchases. Trading financial assets stood at **340 million yuan**, and restricted assets totaled **37.55 million yuan** Significant Changes in Asset Composition | Item | Current Period End Amount (Yuan) | % of Total Assets | Prior Year End Amount (Yuan) | % of Total Assets | % Change | Explanation of Significant Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Monetary Funds | 508,376,485.08 | 27.66% | 958,580,504.06 | 50.88% | -23.22% | Primarily due to purchase of bank wealth management products, leading to a decrease in monetary funds | | Accounts Receivable | 142,876,153.08 | 7.77% | 120,781,153.93 | 6.41% | 1.36% | | | Inventories | 238,469,196.68 | 12.97% | 210,394,935.08 | 11.17% | 1.80% | | | Fixed Assets | 231,061,600.23 | 12.57% | 223,518,586.70 | 11.87% | 0.70% | | | Construction in Progress | 220,902,751.18 | 12.02% | 216,589,868.20 | 11.50% | 0.52% | | | Short-Term Borrowings | 950,000.00 | 0.05% | 0.00 | 0.00% | 0.05% | | | Contract Liabilities | 8,243,855.61 | 0.45% | 4,013,646.82 | 0.21% | 0.24% | | - The company has no major overseas assets during the reporting period [42](index=42&type=chunk) Assets and Liabilities Measured at Fair Value | Item | Beginning Balance (Yuan) | Amount Purchased in Current Period (Yuan) | Amount Sold in Current Period (Yuan) | Ending Balance (Yuan) | | :--- | :--- | :--- | :--- | :--- | | Trading Financial Assets | 0.00 | 1,299,999,640.00 | 960,000,000.00 | 339,999,640.00 | | Receivables Financing | 26,819,710.96 | 0.00 | 0.00 | 17,599,254.98 | | Total | 26,819,710.96 | 1,299,999,640.00 | 960,000,000.00 | 357,598,894.98 | Restricted Asset Information | Item | Period-End Book Balance (Yuan) | Type of Restriction | Reason for Restriction | | :--- | :--- | :--- | :--- | | Monetary Funds | 21,245,134.89 | Pledge | Bills, letter of guarantee deposits | | Notes Receivable | 16,309,854.47 | Pledge | Endorsed notes receivable not derecognized | | Total | 37,554,989.36 | | | [VI. Investment Status Analysis](index=12&type=section&id=VI.%20Investment%20Status%20Analysis) Total investments surged by **5167.01%** to **1.33 billion yuan**, mainly due to bank wealth management product purchases. Raised funds of **373 million yuan** (**59.41%** of net) were primarily allocated to key projects and working capital. Company entrusted wealth management totaled **1.3 billion yuan** Investment Amount During the Reporting Period | Indicator | Investment Amount in Current Period (Yuan) | Investment Amount in Prior Year (Yuan) | Change Rate | | :--- | :--- | :--- | :--- | | Investment Amount | 1,329,903,042.13 | 25,249,691.97 | 5,167.01% | - The company had no significant equity investments or non-equity investments during the reporting period [46](index=46&type=chunk) Overall Utilization of Raised Funds | Total Raised Funds (10,000 Yuan) | Net Raised Funds (10,000 Yuan) | Total Raised Funds Used in Current Period (10,000 Yuan) | Total Raised Funds Used Cumulatively (10,000 Yuan) | % of Raised Funds Used at Period End | | :--- | :--- | :--- | :--- | :--- | | 71,343.2 | 62,816.77 | 37,317.03 | 37,317.03 | 59.41% | - Raised funds are primarily used for the 100 tons/year precious metal catalyst, 60 tons/year high-end luminescent new materials, 4100 tons/year high-end organic iodine and bromine new materials projects, and the 1000 tons/year contrast agent intermediates project, as well as supplementing working capital [48](index=48&type=chunk)[49](index=49&type=chunk) - The company has completed the replacement of self-raised funds pre-invested in raised fund projects and already paid issuance expenses, totaling **233.6607 million yuan** [50](index=50&type=chunk) Overview of Entrusted Wealth Management | Specific Type | Amount of Entrusted Wealth Management (10,000 Yuan) | Unmatured Balance (10,000 Yuan) | | :--- | :--- | :--- | | Bank Wealth Management Products (Raised Funds) | 49,999.96 | 14,999.96 | | Bank Wealth Management Products (Own Funds) | 80,000.00 | 19,000.00 | | Total | 129,999.96 | 33,999.96 | - The company had no derivative investments or entrusted loans during the reporting period [54](index=54&type=chunk)[55](index=55&type=chunk) [VII. Significant Asset and Equity Sales](index=17&type=section&id=VII.%20Significant%20Asset%20and%20Equity%20Sales) The company did not engage in any significant asset or equity sales during the reporting period - The company did not sell significant assets during the reporting period [56](index=56&type=chunk) - The company did not sell significant equity during the reporting period [57](index=57&type=chunk) [VIII. Analysis of Major Holding and Participating Companies](index=17&type=section&id=VIII.%20Analysis%20of%20Major%20Holding%20and%20Participating%20Companies) The company has no significant holding or participating company information to disclose for the reporting period - The company has no significant holding or participating company information to disclose during the reporting period [57](index=57&type=chunk) [IX. Information on Structured Entities Controlled by the Company](index=17&type=section&id=IX.%20Information%20on%20Structured%20Entities%20Controlled%20by%20the%20Company) The company did not control any structured entities during the reporting period - The company did not control any structured entities during the reporting period [58](index=58&type=chunk) [X. Risks Faced by the Company and Countermeasures](index=17&type=section&id=X.%20Risks%20Faced%20by%20the%20Company%20and%20Countermeasures) Company faces risks from raw material price volatility, iodine procurement, policy changes, and environmental protection. Countermeasures include R&D, talent, organizational, IT, and performance management enhancements - The company faces risks from fluctuations in raw material (iodine, precious metals) prices, which could directly impact production costs and profitability [58](index=58&type=chunk) - Iodine element procurement carries risks, primarily relying on imports and affected by international politics, policies, and resource depletion; procurement of iodine-containing waste is also influenced by changes in the pharmaceutical industry environment [59](index=59&type=chunk) - The company is involved in hazardous chemical production and comprehensive hazardous waste treatment, facing risks from increasingly stringent industrial policies, safety production, and environmental protection [60](index=60&type=chunk)[61](index=61&type=chunk)[62](index=62&type=chunk)[63](index=63&type=chunk) - Countermeasures include continuous increase in R&D investment, innovative recruitment and talent incentives, optimization of organizational structure, strengthening digital and informatization construction, and enhancing budget and performance appraisal [64](index=64&type=chunk)[65](index=65&type=chunk)[66](index=66&type=chunk)[67](index=67&type=chunk)[68](index=68&type=chunk) [XI. Registration Form for Research, Communication, Interview, and Other Activities During the Reporting Period](index=18&type=section&id=XI.%20Registration%20Form%20for%20Research%2C%20Communication%2C%20Interview%2C%20and%20Other%20Activities%20During%20the%20Reporting%20Period) The company actively engaged in investor relations activities, hosting institutional investors and participating in performance briefings to discuss company performance, future plans, industry trends, and core competencies - During the reporting period, the company hosted multiple institutional investors for on-site research and online communication, including Qingdao Tiancheng Fund, Haitong Securities, China Life, Zhongtai Securities, O Fund, Boshi Fund, CITIC Securities, Changjiang Securities, Hongshang Asset, and Gechuan Asset [69](index=69&type=chunk)[70](index=70&type=chunk) - Communication topics primarily focused on company performance, future development plans, industry trends, application areas of iodide products, customers and capacity, core competencies and industry barriers, and future talent development plans [69](index=69&type=chunk)[70](index=70&type=chunk) [XII. Formulation and Implementation of Market Value Management System and Valuation Enhancement Plan](index=20&type=section&id=XII.%20Formulation%20and%20Implementation%20of%20Market%20Value%20Management%20System%20and%20Valuation%20Enhancement%20Plan) The company has not formulated a market value management system nor disclosed a valuation enhancement plan - The company has not formulated a market value management system [71](index=71&type=chunk) - The company has not disclosed a valuation enhancement plan [71](index=71&type=chunk) [XIII. Implementation of "Quality and Return Dual Enhancement" Action Plan](index=20&type=section&id=XIII.%20Implementation%20of%20%22Quality%20and%20Return%20Dual%20Enhancement%22%20Action%20Plan) The company has not disclosed an announcement regarding the "Quality and Return Dual Enhancement" action plan - The company has not disclosed an announcement regarding the "Quality and Return Dual Enhancement" action plan [71](index=71&type=chunk) Part IV Corporate Governance, Environment, and Society [I. Changes in Directors, Supervisors, and Senior Management](index=21&type=section&id=I.%20Changes%20in%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) There were no changes in the company's directors, supervisors, or senior management during the reporting period - There were no changes in the company's directors, supervisors, and senior management during the reporting period [73](index=73&type=chunk) [II. Profit Distribution and Capital Reserve to Share Capital Conversion in Current Period](index=21&type=section&id=II.%20Profit%20Distribution%20and%20Capital%20Reserve%20to%20Share%20Capital%20Conversion%20in%20Current%20Period) The company proposes a cash dividend of **2 yuan per 10 shares** (including tax) based on **133,640,000 shares**, totaling **26,728,000.00 yuan**, with no bonus shares or capital reserve conversion Current Period Profit Distribution Plan | Indicator | Content | | :--- | :--- | | Number of Bonus Shares per 10 Shares | 0 shares | | Dividend per 10 Shares (including tax) | 2 yuan | | Share Capital Base for Distribution Plan | 133,640,000 shares | | Cash Dividend Amount (including tax) | 26,728,000.00 yuan | | Ratio of Total Cash Dividend to Total Profit Distribution | 100.00% | | Distributable Profit | 670,156,510.48 yuan | - This profit distribution plan has been approved by the Tenth Meeting of the Second Board of Directors and the Eighth Meeting of the Second Supervisory Board, and it meets the authorization of the shareholders' meeting, thus not requiring re-submission to the shareholders' meeting [75](index=75&type=chunk) [III. Implementation of Company Equity Incentive Plans, Employee Stock Ownership Plans, or Other Employee Incentive Measures](index=21&type=section&id=III.%20Implementation%20of%20Company%20Equity%20Incentive%20Plans%2C%20Employee%20Stock%20Ownership%20Plans%2C%20or%20Other%20Employee%20Incentive%20Measures) The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures in place or implemented during the reporting period - The company had no equity incentive plans, employee stock ownership plans, or other employee incentive measures and their implementation during the reporting period [76](index=76&type=chunk) [IV. Environmental Information Disclosure](index=22&type=section&id=IV.%20Environmental%20Information%20Disclosure) The company and its main subsidiary are listed as legally required environmental information disclosure enterprises and have published their environmental information online - The company and its main subsidiary, Shandong Boyuan Pharmaceutical Chemical Co., Ltd., are included in the list of enterprises legally required to disclose environmental information [77](index=77&type=chunk) - The company has publicly disclosed its environmental information disclosure report at http://221.214.62.226:8090/EnvironmentDisclosure/ [77](index=77&type=chunk) [V. Social Responsibility](index=22&type=section&id=V.%20Social%20Responsibility) Guided by its mission, the company fulfills its social responsibilities to investors, the environment, safety, customers, suppliers, and employees, striving for high-quality development and shared social value - The company highly values investor rights protection, establishing diversified communication channels, strictly disclosing information, and plans to continue cash dividends based on 2025 semi-annual report data [79](index=79&type=chunk) - The company adheres to the "technological innovation, green development" philosophy, strictly complies with environmental regulations, and builds a circular economy model; in terms of safety production, it implements "safety first, prevention foremost," establishing the "Gong Zhi Dao" safety management platform to modernize safety management [80](index=80&type=chunk) - The company operates with "customer-centric, integrity and professionalism, win-win cooperation" as its values, strictly fulfilling contracts, focusing on product quality, and diligently meeting payment obligations to suppliers [81](index=81&type=chunk) - The company strictly complies with the Labor Law, implements employment systems and social security according to law, focuses on employee growth and career development, and establishes a comprehensive training system and performance appraisal mechanism [82](index=82&type=chunk) Part V Significant Matters [I. Commitments Fulfilled and Overdue Unfulfilled by Actual Controllers, Shareholders, Related Parties, Acquirers, and the Company During and as of the End of the Reporting Period](index=23&type=section&id=I.%20Commitments%20Fulfilled%20and%20Overdue%20Unfulfilled%20by%20Actual%20Controllers%2C%20Shareholders%2C%20Related%20Parties%2C%20Acquirers%2C%20and%20the%20Company%20During%20and%20as%20of%20the%20End%20of%20the%20Reporting%20Period) The company reports no commitments by actual controllers, shareholders, related parties, acquirers, or the company that were fulfilled or overdue and unfulfilled during or as of the end of the reporting period - The company reports no commitments by actual controllers, shareholders, related parties, acquirers, or the company that were fulfilled during or overdue and unfulfilled as of the end of the reporting period [84](index=84&type=chunk) [II. Non-Operating Funds Occupied by Controlling Shareholders and Other Related Parties from the Listed Company](index=23&type=section&id=II.%20Non-Operating%20Funds%20Occupied%20by%20Controlling%20Shareholders%20and%20Other%20Related%20Parties%20from%20the%20Listed%20Company) The company reports no non-operating funds occupied by controlling shareholders or other related parties from the listed company during the reporting period - The company reports no non-operating funds occupied by controlling shareholders and other related parties from the listed company during the reporting period [85](index=85&type=chunk) [III. Irregular External Guarantees](index=23&type=section&id=III.%20Irregular%20External%20Guarantees) The company had no irregular external guarantees during the reporting period - The company had no irregular external guarantees during the reporting period [86](index=86&type=chunk) [IV. Appointment and Dismissal of Accounting Firms](index=23&type=section&id=IV.%20Appointment%20and%20Dismissal%20of%20Accounting%20Firms) The company's semi-annual financial report was not audited - The company's semi-annual report was not audited [87](index=87&type=chunk) [V. Explanation by the Board of Directors, Supervisory Board, and Audit Committee on the Accounting Firm's "Non-Standard Audit Report" for the Current Period](index=23&type=section&id=V.%20Explanation%20by%20the%20Board%20of%20Directors%2C%20Supervisory%20Board%2C%20and%20Audit%20Committee%20on%20the%20Accounting%20Firm's%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Current%20Period) The company had no non-standard audit report during the reporting period - The company had no non-standard audit report during the reporting period [88](index=88&type=chunk) [VI. Explanation by the Board of Directors on the "Non-Standard Audit Report" for the Previous Year](index=23&type=section&id=VI.%20Explanation%20by%20the%20Board%20of%20Directors%20on%20the%20%22Non-Standard%20Audit%20Report%22%20for%20the%20Previous%20Year) The company had no non-standard audit report for the previous year during the reporting period - The company had no non-standard audit report for the previous year during the reporting period [88](index=88&type=chunk) [VII. Bankruptcy and Reorganization Matters](index=23&type=section&id=VII.%20Bankruptcy%20and%20Reorganization%20Matters) The company had no bankruptcy and reorganization matters during the reporting period - The company had no bankruptcy and reorganization matters during the reporting period [88](index=88&type=chunk) [VIII. Litigation Matters](index=23&type=section&id=VIII.%20Litigation%20Matters) The company had no significant litigation or arbitration matters, nor any other litigation matters, during the reporting period - The company had no significant litigation or arbitration matters during the reporting period [89](index=89&type=chunk) - The company had no other litigation matters during the reporting period [89](index=89&type=chunk) [IX. Penalties and Rectification](index=24&type=section&id=IX.%20Penalties%20and%20Rectification) The company had no penalties or rectification situations during the reporting period - The company had no penalties or rectification situations during the reporting period [90](index=90&type=chunk) [X. Integrity Status of the Company, its Controlling Shareholders, and Actual Controllers](index=24&type=section&id=X.%20Integrity%20Status%20of%20the%20Company%2C%20its%20Controlling%20Shareholders%2C%20and%20Actual%20Controllers) The company, its controlling shareholders, and actual controllers maintained a good integrity status during the reporting period, with no inapplicable situations - The company reports no inapplicable situations regarding the integrity status of the company, its controlling shareholders, and actual controllers during the reporting period [91](index=91&type=chunk) [XI. Significant Related Party Transactions](index=24&type=section&id=XI.%20Significant%20Related%20Party%20Transactions) The company did not engage in any significant related party transactions during the reporting period, including those related to daily operations, asset/equity acquisition/disposal, joint investments, or intercompany debt - The company did not engage in related party transactions related to daily operations during the reporting period [91](index=91&type=chunk) - The company did not engage in related party transactions involving asset or equity acquisition/disposal during the reporting period [92](index=92&type=chunk) - The company did not engage in related party transactions involving joint external investments during the reporting period [93](index=93&type=chunk) - The company had no related party creditor-debtor relationships during the reporting period [94](index=94&type=chunk) - There were no deposits, loans, credit lines, or other financial services between the company and related financial companies, or between financial companies controlled by the company and related parties [95](index=95&type=chunk)[96](index=96&type=chunk) - The company had no other significant related party transactions during the reporting period [97](index=97&type=chunk) [XII. Significant Contracts and Their Performance](index=25&type=section&id=XII.%20Significant%20Contracts%20and%20Their%20Performance) The company had no significant contracts, including those for trusteeship, contracting, leasing, or guarantees, during the reporting period - The company had no trusteeship, contracting, or leasing situations during the reporting period [98](index=98&type=chunk)[99](index=99&type=chunk)[100](index=100&type=chunk) - The company had no significant guarantee situations during the reporting period [101](index=101&type=chunk) - The company had no other significant contracts during the reporting period [104](index=104&type=chunk) [XIII. Explanation of Other Significant Matters](index=25&type=section&id=XIII.%20Explanation%20of%20Other%20Significant%20Matters) The company acquired **100% equity** of its wholly-owned subsidiary Weifang Rongyuan New Materials Co., Ltd. on February 6, 2025, and completed its absorption merger and cancellation on July 2, 2025, with all assets and liabilities assumed by the company, having no material impact on consolidated financial statements - On February 6, 2025, the company approved the acquisition of 100% equity of Weifang Rongyuan New Materials Co., Ltd. and included it in the scope of consolidated financial statements [105](index=105&type=chunk) - On July 2, 2025, Weifang Rongyuan completed its industrial and commercial deregistration, with all its assets, claims, debts, business, personnel, and relevant qualifications assumed by Boyuan Chemical [106](index=106&type=chunk) - This absorption merger has been completed and will not have a material impact on the company's consolidated financial statements, nor will it significantly affect the company's financial and operational situation [106](index=106&type=chunk) [XIV. Significant Matters of Company Subsidiaries](index=26&type=section&id=XIV.%20Significant%20Matters%20of%20Company%20Subsidiaries) The company's subsidiaries had no other significant matters during the reporting period - The company's subsidiaries had no significant matters during the reporting period [107](index=107&type=chunk) Part VI Share Changes and Shareholder Information [I. Share Change Information](index=27&type=section&id=I.%20Share%20Change%20Information) The company's total share capital increased from **102.8 million shares** to **133.64 million shares** due to the 2024 profit distribution and capital reserve conversion (**3 shares for every 10**). Additionally, **1.72 million shares** from initial public offering offline placement were unlocked and listed on June 11, 2025 Share Change Information | Share Type | Quantity Before Change (Shares) | % Before Change | Increase/Decrease in Current Period (Shares) | Quantity After Change (Shares) | % After Change | | :--- | :--- | :--- | :--- | :--- | :--- | | I. Restricted Shares | 78,426,694 | 76.29% | 21,803,306 | 100,230,000 | 75.00% | | II. Unrestricted Shares | 24,373,306 | 23.71% | 9,036,694 | 33,410,000 | 25.00% | | III. Total Shares | 102,800,000 | 100.00% | 30,840,000 | 133,640,000 | 100.00% | - The main reason for share changes was the company's implementation of the 2024 profit distribution and capital reserve to share capital conversion plan on May 15, 2025, transferring **3 shares for every 10 shares** based on 102,800,000 shares, totaling **30,840,000 shares** [111](index=111&type=chunk) - On June 11, 2025, **1,724,702 shares** from the initial public offering's offline placement, previously restricted, were unlocked and listed for trading, accounting for **1.29% of total share capital** [112](index=112&type=chunk) Changes in Restricted Shares | Shareholder Name | Beginning Restricted Shares (Shares) | Shares Unlocked in Current Period (Shares) | Shares Increased in Current Period (Shares) | Ending Restricted Shares (Shares) | Reason for Restriction | Proposed Unlocking Date | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Li Chenglin | 31,250,000 | 0 | 9,375,000 | 40,625,000 | Restricted shares before IPO | December 10, 2027 | | Yu Guoqing | 27,250,000 | 0 | 8,175,000 | 35,425,000 | Restricted shares before IPO | December 10, 2027 | | Zhongmin Tianhe (Tianjin) Investment Management Co., Ltd. - Weifang Jintou New and Old Kinetic Energy Conversion Equity Investment Partnership (Limited Partnership) | 9,371,800 | 0 | 2,811,540 | 12,183,340 | Restricted shares before IPO | December 10, 2025 | | Restricted shares from IPO offline placement | 1,326,694 | 1,724,702 | 398,008 | 0 | Restricted shares from IPO offline placement | Unlocked on June 11, 2025 | [II. Securities Issuance and Listing](index=29&type=section&id=II.%20Securities%20Issuance%20and%20Listing) The company had no securities issuance or listing activities during the reporting period - The company had no securities issuance or listing activities during the reporting period [117](index=117&type=chunk) [III. Shareholder Numbers and Shareholding](index=29&type=section&id=III.%20Shareholder%20Numbers%20and%20Shareholding) As of the reporting period end, the company had **15,726 common shareholders**. Li Chenglin and Yu Guoqing are controlling shareholders, holding **30.40%** and **26.51%** respectively, with a high proportion of restricted shares among top shareholders and some related party/concerted action relationships - The total number of common shareholders at the end of the reporting period was **15,726** [118](index=118&type=chunk) Shareholding of Shareholders Holding 5% or More or Top 10 Shareholders | Shareholder Name | Shareholder Nature | Shareholding Ratio | Shares Held at Period End (Shares) | Change in Current Period (Shares) | Restricted Shares Held (Shares) | Unrestricted Shares Held (Shares) | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | Li Chenglin | Domestic Natural Person | 30.40% | 40,625,000 | 9,375,000 | 40,625,000 | 0 | | Yu Guoqing | Domestic Natural Person | 26.51% | 35,425,000 | 8,175,000 | 35,425,000 | 0 | | Zhongmin Tianhe (Tianjin) Investment Management Co., Ltd. - Weifang Jintou New and Old Kinetic Energy Conversion Equity Investment Partnership (Limited Partnership) | Other | 9.12% | 12,183,340 | 2,811,540 | 12,183,340 | 0 | | Weifang Dingju Investment Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 2.92% | 3,900,000 | 900,000 | 3,900,000 | 0 | | Jiaxing Lechengyuanhe Equity Investment Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 2.14% | 2,860,000 | 660,000 | 2,860,000 | 0 | | Weifang Zhishuo Investment Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 1.95% | 2,600,000 | 600,000 | 2,600,000 | 0 | | Shanghai Mulan Phase I Private Equity Fund Partnership (Limited Partnership) | Domestic Non-State-Owned Legal Person | 1.46% | 1,950,000 | 450,000 | 1,950,000 | 0 | | Wu Bo | Domestic Natural Person | 0.53% | 706,813 | 706,813 | 0 | 706,813 | | Wang Enxun | Domestic Natural Person | 0.49% | 650,000 | 150,000 | 650,000 | 0 | | Wang Bin | Domestic Natural Person | 0.44% | 592,733 | 425,008 | 0 | 592,733 | - The company's controlling shareholders and actual controllers are Li Chenglin and Yu Guoqing, who are concerted parties. Li Chenglin is the executive partner of Dingju Investment, and Wang Enxun is the brother of Li Chenglin's spouse, both being concerted parties of Li Chenglin. Tianjin Renhe is the employee co-investment platform of Zhongmin Shan Gao, the parent company of Zhongmin Tianhe, the general partner of Weifang Jintou [119](index=119&type=chunk)[120](index=120&type=chunk) [IV. Changes in Shareholdings of Directors, Supervisors, and Senior Management](index=32&type=section&id=IV.%20Changes%20in%20Shareholdings%20of%20Directors%2C%20Supervisors%2C%20and%20Senior%20Management) Shareholdings of certain directors, supervisors, and senior management increased due to the 2024 profit distribution and capital reserve to share capital conversion, including Chairman Li Chenglin, Vice Chairman and General Manager Yu Guoqing, and Director and Deputy General Manager Wang Enxun Changes in Shareholdings of Directors, Supervisors, and Senior Management | Name | Position | Beginning Shareholding (Shares) | Shares Increased in Current Period (Shares) | Ending Shareholding (Shares) | | :--- | :--- | :--- | :--- | :--- | | Li Chenglin | Chairman | 31,250,000 | 9,375,000 | 40,625,000 | | Yu Guoqing | Vice Chairman, General Manager | 27,250,000 | 8,175,000 | 35,425,000 | | Wang Enxun | Director, Deputy General Manager | 500,000 | 150,000 | 650,000 | | Total | -- | 59,000,000 | 17,700,000 | 76,700,000 | - All changes in shareholdings of directors, supervisors, and senior management were due to the implementation of the 2024 annual equity distribution plan, which involved a cash dividend of **3 yuan per 10 shares (including tax)** and a capital reserve to share capital conversion of **3 shares for every 10 shares** [121](index=121&type=chunk) [V. Changes in Controlling Shareholder or Actual Controller](index=32&type=section&id=V.%20Changes%20in%20Controlling%20Shareholder%20or%20Actual%20Controller) There were no changes in the company's controlling shareholder or actual controller during the reporting period - The company's controlling shareholder did not change during the reporting period [122](index=122&type=chunk) - The company's actual controller did not change during the reporting period [122](index=122&type=chunk) [VI. Preferred Share Information](index=32&type=section&id=VI.%20Preferred%20Share%20Information) The company had no preferred shares during the reporting period - The company had no preferred shares during the reporting period [123](index=123&type=chunk) Part VII Bond-Related Information [Bond-Related Information](index=33&type=section&id=Part%20VII%20Bond-Related%20Information) The company had no bond-related information during the reporting period - The company had no bond-related information during the reporting period [125](index=125&type=chunk) Part VIII Financial Report [I. Audit Report](index=34&type=section&id=I.%20Audit%20Report) The company's semi-annual financial report was not audited - The company's semi-annual financial report was not audited [127](index=127&type=chunk) [II. Financial Statements](index=34&type=section&id=II.%20Financial%20Statements) This section provides the company's 2025 semi-annual consolidated and parent company balance sheets, income statements, cash flow statements, and statements of changes in owner's equity, offering a comprehensive view of its financial position, operating results, and cash flows - Financial statements include consolidated balance sheet, parent company balance sheet, consolidated income statement, parent company income statement, consolidated cash flow statement, parent company cash flow statement, consolidated statement of changes in owner's equity, and parent company statement of changes in owner's equity [128](index=128&type=chunk)[132](index=132&type=chunk)[136](index=136&type=chunk)[140](index=140&type=chunk)[144](index=144&type=chunk)[146](index=146&type=chunk)[148](index=148&type=chunk)[155](index=155&type=chunk) [III. Company Basic Information](index=52&type=section&id=III.%20Company%20Basic%20Information) Shandong Boyuan Pharmaceutical Chemical Co., Ltd., established on September 29, 2020, with a registered capital of **133.64 million yuan**, listed on the Shenzhen Stock Exchange on December 11, 2024, primarily engages in R&D, production, and sales of iodides and specialty functional chemicals - The company was wholly converted into a joint-stock company on September 29, 2020, with a registered capital of **133,640,000.00 yuan** and a total of **133,640,000 shares** [163](index=163&type=chunk) - The company's shares were listed and traded on the Shenzhen Stock Exchange on December 11, 2024 [163](index=163&type=chunk) - The company's main business is the R&D, production, and sales of iodides and specialty functional chemicals, as well as chemical trading, belonging to the chemical raw materials and chemical products manufacturing industry [163](index=163&type=chunk) [IV. Basis of Financial Statement Preparation](index=52&type=section&id=IV.%20Basis%20of%20Financial%20Statement%20Preparation) The company's financial statements are prepared on a going concern basis, with no significant doubts about its ability to continue as a going concern for the next 12 months from the reporting period end - The company's financial statements are prepared on a going concern basis [164](index=164&type=chunk) - There are no matters or circumstances that cause significant doubt about the company's ability to continue as a going concern for the next 12 months from the end of the reporting period [165](index=165&type=chunk) [V. Significant Accounting Policies and Estimates](index=52&type=section&id=V.%20Significant%20Accounting%20Policies%20and%20Estimates) This section details the company's accounting policies and estimates for financial instrument impairment, inventory, fixed assets, construction in progress, intangible assets, and revenue recognition, affirming compliance with accounting standards and outlining basic accounting information - The company's financial statements comply with enterprise accounting standards, accurately and completely reflecting its financial position, operating results, and cash flows [167](index=167&type=chunk) - The accounting period is from January 1, 2025, to June 30, 2025; the operating cycle is short, with 12 months used as the liquidity classification standard for assets and liabilities, and RMB as the functional currency [168](index=168&type=chunk)[169](index=169&type=chunk)[170](index=170&type=chunk) - The company has established specific accounting policies and estimates for financial instruments, inventories, fixed assets, construction in progress, intangible assets, and revenue recognition, detailing the classification, recognition, measurement, and derecognition criteria for financial assets and liabilities [166](index=166&type=chunk)[179](index=179&type=chunk)[180](index=180&type=chunk)[190](index=190&type=chunk) - The company accrues loss provisions for financial assets like accounts receivable based on expected credit losses, detailing the measurement methods and key parameters for expected credit losses [194](index=194&type=chunk)[195](index=195&type=chunk) - Revenue recognition principles are based on the fulfillment point or period of performance obligations, and measurement principles consider transaction price, variable consideration, and significant financing components [242](index=242&type=chunk)[243](index=243&type=chunk)[244](index=244&type=chunk) - The company extracts safety production fees according to regulations from the Ministry of Finance and the Ministry of Emergency Management, charging them to relevant product costs or current profit/loss, and simultaneously recording them in the "Special Reserve" account [266](index=266&type=chunk) [VI. Taxes](index=68&type=section&id=VI.%20Taxes) The company's main taxes include VAT, urban maintenance and construction tax, corporate income tax, education surcharge, local education surcharge, and property tax. As a high-tech enterprise, it enjoys a **15%** corporate income tax rate, while subsidiaries Boyuan Xinda and Weifang Rongyuan pay **20%** as small low-profit enterprises Main Tax Categories and Rates | Tax Type | Tax Basis | Tax Rate | | :--- | :--- | :--- | | Value-Added Tax | Sales of goods and taxable services, calculated as output tax minus input tax | 13%, 6%, 5% | | Urban Maintenance and Construction Tax | Actual amount of turnover tax paid | 7% | | Corporate Income Tax | Taxable income | 15%, 20% | | Education Surcharge | Actual amount of turnover tax paid | 3% | | Local Education Surcharge | Actual amount of turnover tax paid | 2% | | Property Tax | Based on 1.2% of original value less 30%; based on 12% of rental income for rental properties | 1.2%, 12% | - The company obtained its high-tech enterprise certificate in December 2022, and its corporate income tax for 2025 is calculated at a reduced rate of **15%** [269](index=269&type=chunk) - Subsidiaries Boyuan Xinda Co., Ltd. and Weifang Rongyuan Co., Ltd. are eligible for small low-profit enterprise policy in 2025, with corporate income tax calculated at **25% of taxable income** and paid at a **20% tax rate** [269](index=269&type=chunk) [VII. Notes to Consolidated Financial Statement Items](index=69&type=section&id=VII.%20Notes%20to%20Consolidated%20Financial%20Statement%20Items) This section provides detailed notes on consolidated financial statement items, including assets, liabilities, equity, income, costs, and expenses, with specific explanations and data for each significant change Period-End Balance of Monetary Funds | Item | Period-End Balance (Yuan) | | :--- | :--- | | Cash on Hand | 24,082.58 | | Bank Deposits | 487,107,267.61 | | Other Monetary Funds | 21,245,134.89 | | Total | 508,376,485.08 | Period-End Balance of Trading Financial Assets | Item | Period-End Balance (Yuan) | | :--- | :--- | | Bank Wealth Management | 339,999,640.00 | | Total | 339,999,640.00 | Period-End Balance of Notes Receivable | Item | Period-End Balance (Yuan) | | :--- | :--- | | Bank Acceptance Bills | 29,250,570.83 | | Total | 29,250,570.83 | Period-End Book Value of Accounts Receivable | Category | Period-End Book Value (Yuan) | | :--- | :--- | | Accounts Receivable for which Bad Debt Provisions are Accrued by Portfolio | 142,876,153.08 | | Total | 142,876,153.08 | Period-End Book Value of Inventories | Item | Period-End Book Value (Yuan) | | :--- | :--- | | Raw Materials | 87,095,310.19 | | Work in Progress | 71,984,965.81 | | Finished Goods | 79,055,149.08 | | Goods in Transit | 333,771.60 | | Total | 238,469,196.68 | Period-End Book Value of Fixed Assets | Item | Period-End Book Value (Yuan) | | :--- | :--- | | Buildings and Structures | 127,037,563.44 | | General Equipment | 1,394,920.45 | | Specialized Equipment | 100,157,382.52 | | Transportation Vehicles | 2,471,733.82 | | Total | 231,061,600.23 | Period-End Balance of Construction in Progress | Item | Period-End Balance (Yuan) | | :--- | :--- | | 100 tons/year Precious Metal Catalyst, 60 tons/year High-End Luminescent New Materials, 4100 tons/year High-End Organic Iodine and Bromine New Materials Project | 124,255,399.75 | | 1,000 tons/year Contrast Agent Intermediates Project | 47,427,359.57 | | Potassium Iodide Solution Purification Project | 8,987,194.21 | | Minor Projects | 33,344,685.99 | | Engineering Materials | 6,888,111.66 | | Total | 220,902,751.18 | Operating Revenue and Operating Cost | Item | Current Period Revenue (Yuan) | Current Period Cost (Yuan) | | :--- | :--- | :--- | | Main Business | 724,535,099.81 | 563,664,751.59 | | Other Business | 22,250,555.78 | 21,837,389.77 | | Total | 746,785,655.59 | 585,502,141.36 | Research and Development Expenses | Item | Current Period Amount (Yuan) | | :--- | :--- | | Employee Compensation | 11,731,771.29 | | Direct Input | 11,896,321.81 | | Depreciation and Amortization | 1,646,320.84 | | Other | 180,850.31 | | Total | 25,455,264.25 | Financial Expenses | Item | Current Period Amount (Yuan) | | :--- | :--- | | Interest Expense | 46,189.46 | | Interest Income | -1,207,749.49 | | Exchange Gains/Losses | 1,037,665.27 | | Handling Fees and Other | 110,057.70 | | Total | -13,837.06 | Investment Income | Item | Current Period Amount (Yuan) | | :--- | :--- | | Bill Discounting Loss | -2,014,849.13 | | Wealth Management Income | 2,816,907.19 | | Total | 802,058.06 | [VIII. Research and Development Expenses](index=98&type=section&id=VIII.%20Research%20and%20Development%20Expenses) Total R&D expenses for the current period were **25,455,264.25 yuan**, all expensed, primarily comprising employee compensation, direct input, and depreciation/amortization, representing an **18.35%** increase year-on-year R&D Expense Composition | Item | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Employee Compensation | 11,731,771.29 | 9,224,574.10 | | Direct Input | 11,896,321.81 | 11,547,705.48 | | Depreciation and Amortization | 1,646,320.84 | 693,278.15 | | Technical Service Fees | 0.00 | 4,716.98 | | Other | 180,850.31 | 38,574.73 | | Total | 25,455,264.25 | 21,508,849.44 | | Of which: Expensed R&D Expenditure | 25,455,264.25 | 21,508,849.44 | [IX. Changes in Consolidation Scope](index=99&type=section&id=IX.%20Changes%20in%20Consolidation%20Scope) The company underwent a business combination under common control during the reporting period, acquiring **100% equity** of Weifang Rongyuan New Materials Co., Ltd. on February 28, 2025, and including it in the consolidated financial statements, with its net profit from the beginning of the period to the combination date being **-70,014.53 yuan** Business Combination Under Common Control Occurring in Current Period | Name of Acquiree | Equity Acquired in Business Combination | Combination Date | Net Profit from Beginning of Current Period to Combination Date (Yuan) | | :--- | :--- | :--- | :--- | | Weifang Rongyuan New Materials Co., Ltd. | 100.00% | 2025年02月28日 | -70,014.53 | - The combination cost was **12,500,000.00 yuan** in cash [436](index=436&type=chunk) Book Value of Acquiree's Assets and Liabilities on Combination Date | Item | Combination Date (Yuan) | | :--- | :--- | | Assets | 11,771,301.42 | | Liabilities | 5,109,819.31 | | Net Assets | 6,661,482.11 | [X. Interests in Other Entities](index=100&type=section&id=X.%20Interests%20in%20Other%20Entities) The company holds **100%** equity in Boyuan Xinda Co., Ltd. and Weifang Rongyuan Co., Ltd., with Weifang Rongyuan acquired through a business combination Composition of Enterprise Group | Subsidiary Name | Registered Capital (Yuan) | Shareholding Ratio (Direct) | Acquisition Method | | :--- | :--- | :--- | :--- | | Boyuan Xinda Co., Ltd. | 10,000,000.00 | 100.00% | Establishment | | Weifang Rongyuan Co., Ltd. | 8,000,000.00 | 100.00% | Business Combination | [XI. Government Grants](index=100&type=section&id=XI.%20Government%20Grants) Government grants recognized in current profit or loss totaled **3,342,396.05 yuan**, an increase from the prior year, primarily comprising income-related grants and VAT super deduction Government Grants Included in Current Profit or Loss | Accounting Account | Current Period Amount (Yuan) | Prior Period Amount (Yuan) | | :--- | :--- | :--- | | Government Grants Included in Other Income | 3,342,396.05 | 3,016,988.86 | - Government grants primarily originate from income-related government grants and VAT super deduction [408](index=408&type=chunk) [XII. Risks Related to Financial Instruments](index=101&type=section&id=XII.%20Risks%20Related%20to%20Financial%20Instruments) The company faces credit, liquidity, and market risks (interest rate and foreign exchange). Risk management involves customer credit assessment, placing monetary funds with highly-rated financial institutions, and diversifying financing with appropriate financial instruments. Foreign exchange risk is not significant due to RMB-denominated primary business - The company faces credit risk, liquidity risk, and market risk (interest rate risk and foreign exchange risk) [442](index=442&type=chunk)[456](index=456&type=chunk)[457](index=457&type=chunk)[458](index=458&type=chunk) - Credit risk management includes quantitative and qualitative criteria for significant increases in financial instrument credit risk, and definitions of default and credit-impaired assets [444](index=444&type=chunk)[445](index=445&type=chunk)[446](index=446&type=chunk) - The company controls monetary fund credit risk by depositing bank funds with highly-rated financial institutions and conducting credit assessments for customers transacting on credit [450](index=450&type=chunk)[452](index=452&type=chunk) - Liquidity risk is controlled through a combination of financing methods such as bill settlement, public stock issuance, and appropriate mixes of long-term and short-term financing [454](index=454&type=chunk) - The company's market risk from foreign exchange fluctuations is not significant, as its main activities are denominated in RMB [458](index=458&type=chunk) Financial Assets Derecognized Due to Transfer | Item | Method of Financial Asset Transfer | Amount of Derecognized Financial Assets (Yuan) | Gains or Losses Related to Derecognition (Yuan) | | :--- | :--- | :--- | :--- | | Receivables Financing | Endorsement | 42,380,367.46 | 0.00 | | Receivables Financing | Discounting | 296,645,851.25 | 1,507,479.75 | | Notes Receivable | Discounting | 31,369,740.63 | 233,957.80 | | Total | | 370,395,959.34 | 1,741,437.55 | Financial Assets Transferred with Continuing Involvement | Item | Method of Asset Transfer | Amount of Assets Formed by Continuing Involvement (Yuan) | Amount of Liabilities Formed by Continuing Involvement (Yuan) | | :--- | :--- | :--- | :--- | | Notes Receivable | Endorsement | 16,309,854.47 | 16,309,854.47 | | Notes Receivable | Discounting | 950,000.00 | 950,000.00 | | Total | | 17,259,854.47 | 17,259,854.47 | [XIII. Fair Value Disclosure](index=104&type=section&id=XIII.%20Fair%20Value%20Disclosure) The company's total assets measured at fair value on an ongoing basis at period-end were **357,598,894.98 yuan**, mainly comprising trading financial assets and receivables financing. The book value of financial assets and liabilities not measured at fair value is close to their fair value Fair Value of Assets and Liabilities Measured at Fair Value at Period End | Item | Level 3 Fair Value Measurement (Yuan) | Total (Yuan) | | :--- | :--- | :--- | | Trading Financial Assets | 339,999,640.00 | 339,999,640.00 | | Receivables Financing | 17,599,254.98 | 17,599,254.98 | | Total Assets Measured at Fair Value on an Ongoing Basis | 357,598,894.98 | 357,598,894.98 | - For bank acceptance bills held and bank wealth management products purchased, the initial recognition cost is used as their fair value [467](index=467&type=chunk) - The book value of financial assets and liabilities not measured at fair value (such as monetary funds, notes receivable, accounts receivable) has a small difference from their fair value [468](index=468&type=chunk) [XIV. Related Parties and Related Party Transactions](index=104&type=section&id=XIV.%20Related%20Parties%20and%20Related%20Party%20Transactions) The company's actual controllers are Li Chenglin and Yu Guoqing. Related parties include Wang Enxun, Shandong Lihua Polymer Materials Co., Ltd., Shandong Yuanhua Xinda Investment Co., Ltd., and Shandong Shuoshuo Investment Co., Ltd. Related party transactions during the period included leasing, fund borrowing, and the acquisition of Weifang Rongyuan's **100% equity** for **12.5 million yuan** - The company's actual controllers are Li Chenglin and Yu Guoqing [470](index=470&type=chunk) Other Related Party Information | Other Related Party Name | Relationship with the Company | | :--- | :--- | | Wang Enxun | Brother-in-law of actual controller Li Chenglin's spouse | | Shandong Lihua Polymer Materials Co., Ltd. | Enterprise controlled by actual controllers Li Chenglin and Yu Guoqing | | Shandong Yuanhua Xinda Investment Co., Ltd. | Enterprise controlled by actual controller Li Chenglin | | Shandong Shuoshuo Investment Co., Ltd. | Enterprise controlled by actual controller Yu Guoqing | Related Party Leases (Company as Lessee) | Lessor Name | Type of Leased Asset | Rent Paid in Current Period (Yuan) | | :--- | :--- | :--- | | Wang Enxun | Employee Dormitory | 141,120.00 | | Shandong Lihua Polymer Materials Co., Ltd. | Factory Building, Equipment Lease | 750,000.00 | - Subsidiary Weifang Rongyuan had previously signed loan agreements with related parties Yuanhua Xinda and Shuoshuo Investment, each for **2.5 million yuan**, which were repaid on February 28, 2025 [476](index=476&type=chunk) Key Management Personnel Remuneration | Item | Current Period Amount (Yuan) | | :--- | :--- | | Key Management Personnel Compensation | 3,110,226.54 | - The company acquired **100% equity of Weifang Rongyuan** from Yuanhua Xinda and Shuoshuo Investment for **12.5 million yuan**, constituting a related party transaction completed on February 28, 2025 [479](index=479&type=chunk) Related Party Payables | Item Name | Related Party | Period-End Book Balance (Yuan) | Beginning Book Balance (Yuan) | | :--- | :--- | :--- | :--- | | Employee Dormitory Rent | Wang Enxun | 141,120.00 | 0.00 | | Loan | Yuanhua Xinda | 0.00 | 2,531,506.87 | | Loan | Shuoshuo Investment | 0.00 | 2,531,506.90 | [XV. Share-Based Payment](index=107&type=section&id=XV.%20Share-Based%20Payment) The company has an equity-settled share-based payment plan, with outstanding equity instruments having exercise prices ranging from **4 to 4.08 yuan per share** and a remaining contractual term of **30 months**. The total equity-settled share-based payment expense recognized this period was **457,727.10 yuan**, allocated across various personnel categories Outstanding Other Equity Instruments at Period End | Category of Grantee | Range of Exercise Prices | Remaining Contractual Term | | :--- | :--- | :--- | | Management Personnel | 4 yuan/share | 30 months | | R&D Personnel | 4.04 yuan/share, 4.08 yuan/share | 30 months | | Sales Personnel | 4.04 yuan/share, 4.08 yuan/share | 30 months | | Production Personnel | 4.04 yuan/share, 4.06 yuan/share, 4.08 yuan/share | 30 months | - The fair value of equity instruments on the grant date was determined by referencing recent external investor share prices or the most recent year's net profit multiplied by a reasonable P/E ratio [485](index=485&type=chunk) - The cumulative amount of equity-settled share-based payments recognized in capital reserve is **2,228,193.48 yuan** [485](index=485&type=chunk) Share-Based Payment Expense for Current Period | Category of Grantee | Equity-Settled Share-Based Payment Expense (Yuan) | | :--- | :--- | | Management Personnel | 347,123.90 | | R&D Personnel | 17,015.88 | | Sales Personnel | 51,047.63 | | Production Personnel | 42,539.69 | | Total | 457,727.10 | - There were no modifications or terminations of share-based payments in the current period [487](index=487&type=chunk) [XVI. Commitments and Contingencies](index=108&type=section&id=XVI.%20Commitments%20and%20Contingencies) As of the end of the reporting period, the company had no significant commitments or contingencies requiring disclosure - As of June 30, 2025, the company had no significant commitments requiring disclosure [487](index=487&type=chunk) - As of June 30, 2025, the company had no significant contingencies requiring disclosure [488](index=488&type=chunk) [XVII. Events After the Balance Sheet Date](index=108&type=section&id=XVII.%20Events%20After%20the%20Balance%20Sheet%20Date) The Board of Directors and Supervisory Board approved the 2025 semi-annual profit distribution plan, proposing a cash dividend of **2 yuan per 10 shares** (including tax) based on **133,640,000 shares**, totaling **26,728,000.00 yuan**, with no bonus shares or capital reserve conversion Proposed Profit Distribution | Indicator | Content | | :--- | :--- | | Proposed Dividend per 10 Shares | 2 yuan | | Profit Distribu

证券日报网讯博苑股份（301617）8月12日在互动平台回答投资者提问时表示，截至2025年8月8日，公 司股东总户数为13，252户。 ...

金融界消息 截至2025年7月31日收盘，博苑股份（301617）报收于38.4元，下跌1.49%，换手率4.43%， 成交量1.48万手，成交金额5714.26万元。 资金流向方面，今日主力资金净流出1137.30万元，占比成交额19.9%。其中，超大单净流出136.53万 元、占成交额2.39%，大单净流出1000.77万元、占成交额17.51%，中单净流出流出33.10万元、占成交 额0.58%，小单净流入1170.40万元、占成交额20.48%。 通过天眼查大数据分析，山东博苑医药化学股份有限公司共对外投资了2家企业，参与招投标项目85 次，知识产权方面有商标信息47条，专利信息71条，此外企业还拥有行政许可119个。 来源：金融界 博苑股份最新一期业绩显示，截至2025一季报，公司营业总收入3.20亿元、同比增长4.02%，归属净利 润4907.75万元，同比减少4.05%，扣非净利润4849.16万元，同比减少4.87%，流动比率6.461、速动比率 5.255、资产负债率11.22%。 天眼查商业履历信息显示，山东博苑医药化学股份有限公司，成立于2008年，位于潍坊市，是一家以从 事医药制造业为 ...